Company offering ethical reviews suspends activity A US company that provides ethical reviews of clinical trials agreed to halt operations after being warned by the US Food and Drug Administration (FDA) about violating federal guidelines.
The company, Coast IRB of Colorado Springs, Colorado, was ensnared by a governmental investigation unveiled before Congress last month (see Nature 458, 557; 2009). Investigators submitted a fictitious clinical-trial protocol to three independent institutional review boards. Two boards rejected the protocol, with one member calling it "the riskiest thing I've ever seen on this board". But Coast IRB voted unanimously to approve the trial.
On 14 April, the FDA announced that Coast IRB would not approve new studies or add additional subjects to ongoing studies until the agency was satisfied that the company had corrected its procedures. The company has been warned by the FDA before, in 2008, for inappropriately expediting review of a clinical-trial protocol.
US and Japan to collaborate on stem-cell technology Rumours of a potential conflict over the exploitation of patents for induced pluripotent stem cell (iPS) technology were put to rest last week. 
IPS technology was pioneered in 2006 by

US medical institute invests in undergraduates
The Howard Hughes Medical Institute (HHMI) is offering up to $85 million in grants to further undergraduate science education at the United States' top research universities.
The HHMI, which is the largest private funder of biomedical research in the United States, last year dedicated $60 million for science teaching at liberal arts colleges. Now, the institute is awarding individual grants of up to $2.2 million over 4 years for proposals from 197 of the nation's most research-intensive institutions.
Schools must register their interest by 14 May, but have until 1 October to apply for the grants, which should focus on student research, faculty development, curriculum development or community outreach.
As a supplement to these institutional grants, applicants may also compete for awards of up to $600,000 to test experimental approaches to tackling specific science education challenges. "We want to encourage faculty to try new things, " says David Asai, director of the HHMI's undergraduate grants programme. "It's hard to anticipate the kinds of ideas that may come forward. "
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Germany joins in with maize moratorium Germany last week banned the cultivation of Monsanto's genetically modified maize (corn), MON810 -the only transgenic crop approved for cultivation in the European Union (EU).
It joins five other countries -France, Austria, Greece, Hungary and Luxembourg -that have outlawed the US firm's pestresistant maize despite its approval under a legally binding EU directive (see Nature 457, 946-947; 2009 ).
Ilse Aigner, Germany's federal agricultural minister, announced the ban on 14 April, just days before the crop would have been sown. Research minister Annette Schavan called the decision "regrettable".
The European Commission says it is analysing the situation. So far, it has not succeeded in forcing the other EU countries to reverse their bans because it cannot muster the required level of support from its 27 member states. 
